GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Net Change in Cash

Shield Therapeutics (LSE:STX) Net Change in Cash : £14.36 Mil (TTM As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Shield Therapeutics's Net Change in Cash for the six months ended in Jun. 2023 was £10.19 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was £14.36 Mil.

Shield Therapeutics Net Change in Cash Historical Data

The historical data trend for Shield Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Net Change in Cash Chart

Shield Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only -3.52 -5.64 -1.20 9.18 -9.30

Shield Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.66 -10.49 -13.47 4.17 10.19

Shield Therapeutics Net Change in Cash Calculation

Shield Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-17.312+-1.865+7.007+2.874
=-9.30

Shield Therapeutics's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-19.896+-1.318+30.13+1.276
=10.19

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £14.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Net Change in Cash
Comparable Companies
LSE:CEL LSE:VLG LSE:AGY LSE:EAH LSE:CHLL LSE:PXS LSE:HELD AQSE:ANA LSE:N4P LSE:ANCR ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
SHIEF:USA 1JS:Germany
Address
Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF
Website
https://www.shieldtherapeutics.com
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.